Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 1.00 |
| ▸ | DRD3 | P35462 | 4/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | CA2 | P00918 | 2/20 | 0.83 |
| ▸ | DRD1 | P21728 | 2/20 | 0.83 |
| ▸ | DRD4 | P21917 | 2/20 | 0.83 |
| ▸ | CA9 | Q16790 | 2/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.83 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.83 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.83 |
| ▸ | LMNA | P02545 | 2/20 | 0.83 |
| ▸ | TSHR | P16473 | 2/20 | 0.83 |
| ▸ | CA12 | O43570 | 1/20 | 0.83 |
| ▸ | CA1 | P00915 | 1/20 | 0.83 |
| ▸ | CA3 | P07451 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sultopride SCHEMBL30213416 | 1.00 | DRD2 (1.00) | DRD2DRD3ADRA2BADRA2CHTR2B | |
| Sultopride SCHEMBL1417863 | 0.99 | DRD2 (0.98) | DRD2DRD3ADRA2BADRA2CHTR2B | |
| Sultopride SCHEMBL8812905 | 0.95 | DRD2 (0.93) | DRD2DRD3ADRA2BADRA2CHTR2B | |
| SCHEMBL11540557 | 0.92 | DRD2 (0.85) | DRD2DRD3ADRA2BADRA2CHTR2B | |
| SCHEMBL28668960 | 0.92 | DRD2 (0.85) | DRD2DRD3ADRA2BADRA2CHTR2B | |
| Amisulpride SCHEMBL1902407 | 0.91 | DRD2 (0.86) | DRD2DRD3ADRA2BADRA2CHTR2B | |
| Sulpiride SCHEMBL15475031 | 0.91 | DRD2 (1.00) | DRD2DRD3ADRA2BADRA2CHTR2B | |
| Sulpiride SCHEMBL29576250 | 0.91 | DRD2 (1.00) | DRD2DRD3ADRA2BADRA2CHTR2B | |
| Levosulpiride SCHEMBL29406121 | 0.91 | DRD2 (1.00) | DRD2DRD3ADRA2BADRA2CHTR2B | |
| Sulpiride SCHEMBL29359128 | 0.91 | DRD2 (1.00) | DRD2DRD3ADRA2BADRA2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1602 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12527754-B2 | Methods and compositions for preventing and treating metabolic syndrome induced by antipsychotic treatment and related diseases and conditions | TUFTS MEDICAL CENTER, INC. (US) | 2026-01-20 | — | — | US | claimed |
| EP-4674482-A2 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS ASSOCIATED WITH NEURODEGENERATIVE DISEASE OR IMPULSIVE SYMPTOMS ASSOCIATED WITH MENTAL DISEASE CONTAINING BREXPIPRAZOLE OR SALT THEREOF | Otsuka Pharmaceutical Co., Ltd. (JP) | 2026-01-07 | — | — | EP | claimed |
| US-20250367212-A1 | PHARMACOTHERAPY FOR OBSESSIVE-COMPULSIVE DISORDER TARGETING DOPAMINE D1 SIGNAL IN STRIATAL STRIOSOMES | MATSUMOTO SHINICHI (JP) | 2025-12-04 | — | — | US | claimed |
| EP-4618973-A1 | METHODS OF SWITCHING NEUROPSYCHIATRIC MEDICATIONS USING ULOTARONT | Sumitomo Pharma America, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| US-20250179064-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | AUSPEX PHARMACEUTICALS LLC | 2025-06-05 | — | — | US | claimed |
| WO-2025101418-A1 | TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS IN PATIENTS WITH PROMINENT ANHEDONIA USING IRDABISANT AS A MONOTHERAPY OR IN COMBINATION WITH AN ANTIPSYCHOTIC AGENT | ALTO NEUROSCIENCE, INC. (US) | 2025-05-15 | — | — | WO | claimed |
| US-20250144092-A1 | TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS IN PATIENTS WITH PROMINENT ANHEDONIA USING IRDABISANT AS A MONOTHERAPY OR IN COMBINATION WITH AN ANTIPSYCHOTIC AGENT | ALTO NEUROSCIENCE, INC. | 2025-05-08 | — | — | US | claimed |
| EP-3923988-B1 | TRIAMTERENE OR NOLATREXED FOR USE IN THE TREATMENT OF PHENYLKETONURIA | SOM INNOVATION BIOTECH S A (ES) | 2025-04-30 | — | — | EP | claimed |
| EP-4541372-A1 | DRUG THERAPY FOR OBSESSIVE-COMPULSIVE DISORDER TARGETING DOPAMINE D1 SIGNAL IN STRIATAL STRIOSOMES | Matsumoto, Shinichi (JP) | 2025-04-23 | — | — | EP | claimed |
| US-20250099459-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS ASSOCIATED WITH NEURODEGENERATIVE DISEASE OR IMPULSIVE SYMPTOMS ASSOCIATED WITH MENTAL DISEASE CONTAINING BREXPIPRAZOLE OR SALT THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-03-27 | — | — | US | claimed |
| EP-1429844-A2 | CONJUGATED ANTI-PSYCHOTIC DRUGS AND USES THEREOF | Ramot at Tel Aviv University Ltd. (IL) | 2004-06-23 | — | — | EP | claimed |
| WO-2003026563-A9 | CONJUGATED ANTI-PSYCHOTIC DRUGS AND USES THEREOF | UNIV RAMOT (IL) | 2004-04-22 | — | — | WO | claimed |
| WO-2003026563-A2 | CONJUGATED ANTI-PSYCHOTIC DRUGS AND USES THEREOF | RAMOT AT TEL AVIV UNIVERSITY LTD. (IL) | 2003-04-03 | — | — | WO | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| US-6150353-A | USE OF MIRTAZAPINE AND AN ANTIPSYCHOTIC DRUG COMBINATIONS ENHANCES THEEFFECT OF THE ANTIPSYCHOTIC AGENT TO BE USED AND ALLOW BETTER MANAGEMENT OF DRUG RELATED TOXICITY AND SIDE EFFECT | AKZO NOBEL N.V. (NL) | 2000-11-21 | — | — | US | claimed |
| WO-2000051563-A1 | PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION COMPRISING A BENZAMIDE AND AT LEAST AN ABSORPTION PROMOTER | SANOFI-SYNTHELABO (FR) | 2000-09-08 | — | — | WO | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0969845-A1 | NEW THERAPEUTIC COMBINATIONS OF MIRTAZAPINE AND ANTIPSYCHOTIC AGENTS, FOR THE TREATMENT OR PROPHYLAXIS OF PSYCHOTIC DISORDERS | Akzo Nobel N.V. (NL) | 2000-01-12 | — | — | EP | claimed |
| WO-1998043646-A1 | NEW THERAPEUTIC COMBINATIONS OF MIRTAZAPINE AND ANTIPSYCHOTIC AGENTS, FOR THE TREATMENT OR PROPHYLAXIS OF PSYCHOTIC DISORDERS | AKZO NOBEL N.V. (NL) | 1998-10-08 | — | — | WO | claimed |
| WO-1996001631-A1 | NOVEL COMBINATION PRODUCT COMPRISING CAPRIPRAMINE AND A NEUROLEPTIC | PIERRE FABRE MEDICAMENT (FR) | 1996-01-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179064-A1 | BENZOQUINOLONE INHIBITORS OF VMAT2 | ACAT2, CPT1A, SLC18A2 | DRD2 2127/4885DRD3 2303/4885ADRA2B 187/4885 |
| US-12527754-B2 | Methods and compositions for preventing and treating metabolic syndrome induced by antipsychotic treatment and related diseases and conditions | GPR119, TPH1, LIPC | DRD2 318/4885DRD3 338/4885ADRA2B 263/4885 |
| US-20250099459-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR BEHAVIORAL AND PSYCHOLOGICAL SYMPTOMS ASSOCIATED WITH NEURODEGENERATIVE DISEASE OR IMPULSIVE SYMPTOMS ASSOCIATED WITH MENTAL DISEASE CONTAINING BREXPIPRAZOLE OR SALT THEREOF | SLC6A3, SLC6A2, SNCA | DRD2 96/4885DRD3 208/4885ADRA2B 532/4885 |
| US-20250144092-A1 | TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS IN PATIENTS WITH PROMINENT ANHEDONIA USING IRDABISANT AS A MONOTHERAPY OR IN COMBINATION WITH AN ANTIPSYCHOTIC AGENT | GRIN2B, DRD2, SLC6A3 | DRD2 2/4885DRD3 11/4885ADRA2B 79/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.